References
- Ano S, Panariti A, Allard B, O'Sullivan M, McGovern TK, Hamamoto Y, Ishii Y, Yamamoto M, Powell WS, Martin JG. 2017. Inflammation and airway hyperresponsiveness after chlorine exposure are prolonged by Nrf2 deficiency in mice. Free Radic Biol Med. 102:1–15.
- Arnold M. 2019. Silverlon's revolutionary technology serves on the battlefield and in the OR; [accessed 2020 Sep 27]. https://www.silverlon.com/newsroom/-silverlons-revolutionary-technology-serves-on-the-battlefield-and-in-the-or.
- Avita Medical Limited. 2019. Avita Medical Limited A.B.N. 28 058 466 523 full financial report for the year ended 30 June 2019; [accessed 2020 27 Sep]. https://www.sec.gov/Archives/edgar/data/1762303/000119312519258836/d608964dex991.htm.
- Balakrishna S, Song W, Achanta S, Doran SF, Liu B, Kaelberer MM, Yu Z, Sui A, Cheung M, Leishman E, et al. 2014. TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 307(2):L158–L172.
- Biomedical Advanced Research and Development Authority. 2020. Biomedical advanced research and development authority (BARDA); [accessed 2020 Sep 7]. https://www.phe.gov/about/barda/Pages/default.aspx.
- Biomedical Advanced Research Development Authority (BARDA)/Contracts Management & Acquisition (CMA). 2020. Office of Biomedical Advanced Research Development Authority (BARDA) Broad Agency Announcement, Amendment 17 (BAA-18-100-SOL-00003).
- BioSpace. 2018. Ology bioservices and RAFA laboratories announce FDA approval of the atropine autoinjector as a medical countermeasure for chemical nerve agents.
- Borak J, Diller WF. 2001. Phosgene exposure: mechanisms of injury and treatment strategies. J Occup Environ Med. 43(2):110–119.
- Bullock JA, Haddow GD, Coppola DP. 2018. Chapter 9, all-hazards emergency response and recovery. In: Pam Chester, Amber Hodge, editors. Homeland security: the essentials. 2nd ed. Amsterdam: Butterworth-Heinemann; p. 227–290.
- Burel G. 2019. Looking ahead – future of the Strategic National Stockpile; [accessed 2020 Sep 7]. https://www.domesticpreparedness.com/healthcare/looking-ahead-future-of-the-strategic-national-stockpile/.
- Catravas JD. 2020. Antidotes against HCI-induced chronic lung injury. Old Dominion University: Office of the Director, National Institutes of Health.
- Centers for Disease Control. 2015. CDC’s CHEMPACK Program—the Stockpile that may protect you from a chemical attack. https://blogs.cdc.gov/publichealthmatters/2015/02/cdcs-chempack-program-the-stockpile-that-may-protect-you-from-a-chemical-attack/.
- Christensen S, Sottrup-Jensen L. 1994. Characterization of two serpins from bovine plasma and milk. Biochem J. 303 (2):383–390.
- Cleary EG, Beierlein JM, Khanuja NS, MCNamee LM, Ledley FD. 2018. Contribution of NIH funding to new drug approvals 2010–2016. Proceedings of the National Academy of Sciences of the United States of America. 115(10):2329–2334.
- Cusnir R, Imberti C, Hider RC, Blower PJ, Ma MT. 2017. Hydroxypyridinone chelators: from iron scavenging to radiopharmaceuticals for PET imaging with gallium-68. Int J Mol Sci. 18(1):116.
- Das R, Blanc PD. 1993. Chlorine gas exposure and the lung: a review. Toxicol Ind Health. 9(3):439–455.
- Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations for 2014: hearings before a Subcommittee of the Committee of Appropriations (Serial 86-214). 2013. Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations for 2014.
- Emergent Biosolutions. 2020. Delivering peace of mind in an uncertain world: 2019 annual report; [accessed 2020 Sep 27]. http://nasdaqomx.mobular.net/nasdaqomx/7/3565/5084/.
- Esbitt D. 2017. Strategic National Stockpile Formulary overview [PowerPoint slides]; [accessed 2020 Nov 8]. https://ftp.cdc.gov/pub/MCMTraining/Course. Presentations_SNS Course_Jun_2017/4 - DSNS formulary prep course June 2017 lt blue.pdf.
- Evans B. 2005. How a company cashed in on anthrax. Daily Press. https://www.dailypress.com/news/dp-anth-day4-bioportdec06-story.html.
- Fukuda S, Ihara K, Lopez E, Cox R, Southan G, Salzman A, Salsbury JR, Prough DS, Enkhbaatar P. 2020. R-107 attenuates severity of acute respiratory distress syndrome induced by chlorine gas inhalation in ovine model. Am J Respir Crit Care Med. 201:A6299.
- Global Biodefense Staff. 2020. 51 FDA approved medical countermeasures backed by BARDA. Global Biodefense; [accessed 2020 Sep 7]. https://globalbiodefense.com/2020/01/12/50-fda-approved-medical-countermeasures-backed-by-barda/.
- Grainge C, Rice P. 2010. Management of phosgene-induced acute lung injury. Clin Toxicol. 48(6):497–508.
- Hendry-Hofer TB, Witeof AE, Ng PC, Mahon SB, Brenner M, Boss GR, Bebarta VS. 2020. Intramuscular sodium tetrathionate as an antidote in a clinically relevant swine model of acute cyanide toxicity. Clin Toxicol. 58(1):29–35.
- Hobson ST, Casillas RP, Richieri RA, Nishimura RN, Weisbart RH, Tuttle R, Reynolds GT, Parseghian MH. 2019. Development of an acute, short-term exposure model for phosgene. Toxicol Mech Methods. 29(8):604–615.
- Ji L, Liu R, Zhang XD, Chen HL, Bai H, Wang X, Zhao HL, Liang X, Hai CX. 2010. N-acetylcysteine attenuates phosgene-induced acute lung injury via up-regulation of Nrf2 expression. Inhal Toxicol. 22(7):535–542.
- Kanju P, Chen Y, Lee W, Yeo M, Lee SH, Romac J, Shahid R, Fan P, Gooden DM, Simon SA, et al. 2016. Small molecule dual-inhibitors of TRPV4 and TRPA1 for attenuation of inflammation and pain. Sci Rep. 6:26894.
- Korch GW. 2016. Product life cycle management and the PHEMCE [PowerPoint slides]; [accessed 2020 Sep 27]. https://www.medicalcountermeasures.gov/media/36964/21_korch_phemce.pdf.
- Laney J, Clark M. 2018. FDA approval of anti-seizure drug provides a new tool for protecting Americans during a chemical attack; [accessed 2020 Sep 27]. https://www.jpeocbrnd.osd.mil/news/news-story/2018/10/24/fda-approval-of-anti-seizure-drug-provides-a-new-tool-for-protecting-americans-during-a-chemical-attack.
- Larsen JC, Disbrow GL. 2017. Project BioShield and the biomedical advanced research development authority: a ten year progress report on meeting U.S. preparedness objectives for threat agents. Clin Infect Dis. 64(10):1430–1434.
- Liu F, Pauluhn J, Trubel H, Wang C. 2014. Single high-dose dexamethasone and sodium salicylate failed to attenuate phosgene-induced acute lung injury in rats. Toxicology. 315:17–23.
- Miller J. 1998. Company led by top admiral buys Michigan Vaccine Lab. The New York Times Sect. A:19. https://www.nytimes.com/1998/07/08/us/company-led-by-top-admiral-buys-michigan-vaccine-lab.html.
- Morim A, Guldner GT. 2020. Chlorine gas toxicity. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
- N. D. 2020. BARDA initiates the procurement of NexoBrid for emergency response; [accessed 2020 Sep 27]. https://www.sec.gov/Archives/edgar/data/1593984/000117891320000022/exhibit_99-1.htm.
- National Institute of Neurological Disorders and Stroke. 2020. CounterACT Program: National Institute of Neurological Disorders and Stroke; [updated 2020 Jun 8; accessed 2020 Sep 7]. https://www.ninds.nih.gov/Current-Research/Trans-Agency-Activities/CounterACT.
- Nuclear Threat Initiative. 2008. U.S. awards smallpox vaccine contract; [accessed 2020 Sep 27]. https://www.nti.org/gsn/article/us-awards-smallpox-vaccine-contract/.
- Rajagopalan S. 2020. Counteract supplement – aspire: air pollution: strategies for personalized intervention to reduce exposure. Case Western Reserve University: Office of the Director, National Institutes of Health.
- Rendell R, Fairhall S, Graham S, Rutter S, Auton P, Smith A, Perrott R, Jugg B. 2018. Assessment of N-acetylcysteine as a therapy for phosgene-induced acute lung injury. Toxicol Lett. 290:145–152.
- Rockwood GA, Thompson DE, Petrikovics I. 2016. Dimethyl trisulfide: a novel cyanide countermeasure. Toxicol Ind Health. 32(12):2009–2016.
- Roxas-Duncan VI, Hale ML, Davis JM, Gorbet JC, Legler PM, Smith LM. 2018. Chapter 16, ricin. In: Bozue J, Cote CK, Glass PJ, editors. Medical aspects of biological warfare. Fort Sam Houston (TX): Office of the Surgeon General, Borden Institute; p. 373–402.
- Rozen L. 2001. The anthrax vaccine scandal. Salon.com; [accessed 2020 Sep 7]. https://www.salon.com/2001/10/15/anthrax_vaccine/.
- Sciuto AM, Hurt HH. 2004. Therapeutic treatments of phosgene-induced lung injury. Inhal Toxicol. 16(8):565–580.
- Sidell FR, Newmark J, McDonough Jh. 2008. Chapter 5, nerve agents. In: Tuorinsky SD, editor. Medical aspects of chemical warfare. Washington (DC): Office of the Surgeon General, Borden Institute; p. 155–220.
- Silverlon. 2019. Silverlon leader featured at Department of Health and Human Services Disaster Preparedness Event. [accessed 2020 Sep 27]. https://www.prnewswire.com/news-releases/silverlon-leader-featured-at-department-of-health-and-human-services-disaster-preparedness-event-300951521.html.
- Soligenix. 2020. RiVax(R) to prevent ricin poisoning; [accessed 2020 Sep 7]. https://www.soligenix.com/pipeline-programs/rivax-to-prevent-ricin-poisoning/.
- U.S. Food and Drug Administration. [date unknown]. Drug approval process [Infographic].
- U.S. Department of Health and Human Resources. 2020a. Product transitions; [accessed 2020 Sep 7]. https://www.phe.gov/Preparedness/mcm/phemce/phemce-myb/FY2018-2022/Pages/product-transitions.aspx.
- U.S. Department of Health and Human Services: Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority. [date unknown]. BARDA strategic plan 2011–2016.
- U.S. Department of Health and Human Resources. 2020b. Strategic National Stockpile; [accessed 2020 Sep 7]. https://www.phe.gov/about/sns/Pages/default.aspx.
- U.S. Department of Health and Human Services FaDACfDEaRCCfBEaRC. 2015. Product development under the Animal Rule: guidance for industry; [accessed 2020 Sep 27]. https://www.fda.gov/media/88625/download.
- U.S. Department of Health and Human Services. 2011. BARDA awards contract to develop Prussian blue for pediatric use contract supports advanced development of Prussian blue for infants ages newborn to two years.
- U.S. Department of Health and Human Services. 2015a. HHS enhances preparedness with new products to treat severe burns.
- U.S. Department of Health and Human Services. 2015b. Public health emergency medical countermeasures enterprise multiyear budget: fiscal years. Washington (DC): Public Health Emergency Medical Countermeasures Enterprise; p. 2016–2020.
- U.S. Department of Health and Human Services. 2016. Public health emergency medical countermeasures enterprise multiyear budget: fiscal years. Washington (DC): Public Health Emergency Medical Countermeasures Enterprise; p. 2017–2021.
- U.S. Department of Health and Human Services. 2017a. Emergency use authorization of medical products and related authorities: guidance for industry and other stakeholders. Silver Springs (MD): Food and Drug Administration OotC, Office of the Chief Scientist, Office of Counterterrorism and Emerging Threats.
- U.S. Department of Health and Human Services. 2017b. Putting America's health first: FY2018 President's budget for HHS. Washington (DC).
- U.S. Department of Health and Human Services. 2018. Putting America's health first: FY2019 President's budget for HHS. Washington (DC).
- U.S. Department of Health and Human Services. 2019a. Public health emergency medical countermeasures enterprise multiyear budget: fiscal years 2018–2022. Washington (DC): Public Health Emergency Medical Countermeasures Enterprise.
- U.S. Department of Health and Human Services. 2019b. Putting America's health first: FY2020 President's budget for HHS. Washington (DC).
- U.S. Department of Health and Human Services. 2019c. Radiological/nuclear medical countermeasures; [accessed 2020 Sep 7]. https://www.medicalcountermeasures.gov/barda/cbrn/radiological-and-nuclear-countermeasures.aspx.
- U.S. Department of Health and Human Services. 2020a. Future challenges; [accessed 2020 Sep 7]. https://www.phe.gov/Preparedness/mcm/phemce/phemce-myb/FY2018-2022/Pages/future-challenges.aspx.
- U.S. Department of Health and Human Services. 2020b. HHS FY2016 budget in brief; [accessed 2020 Sep 20]. https://www.hhs.gov/about/budget/budget-in-brief/cdc/index.html.
- U.S. Department of Health and Human Services. 2020c. HHS FY2017 budget in brief; [accessed 2020 Sep 20]. https://www.hhs.gov/about/budget/fy2017/budget-in-brief/cdc/index.html.
- U.S. Department of Health and Human Services. 2020d. Putting America's health first: FY2021 President's budget for HHS. Washington (DC).
- U.S. Department of Health and Human Services. 2020e. Sustaining the Stockpile; [accessed 2020 Sep 7]. https://www.phe.gov/about/sns/Pages/sustaining.aspx.
- U.S. Department of Health and Human Services: Office of Public Health Emergency Medical Countermeasures in the Office of Public Health Emergency Preparedness. 2006. Project BioShield annual report to Congress: July 2004 through July 2006.
- U.S. Department of Health and Human Services: Office of the Assistant Secretary for Preparedness and Response. 2020. Stockpile responses. https://www.phe.gov/about/sns/Pages/responses.aspx.
- U.S. Department of Health and Human Services: Office of the Assistant Secretary for Preparedness and Response. 2010. Project BioShield annual report: January 2009-December 2009.
- U.S. Department of Health and Human Services: Office of the Assistant Secretary for Preparedness and Response. 2015. Project BioShield annual report: January 2014–December 2014.
- U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). 2016. Non-inferiority clinical trials to establish effectiveness: guidance for industry.
- U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response. 2013. BARDA contract supports the development of a more effective skin graft to help burn patients after a rad/nuke event; [accessed 2020 Sep 20]. https://www.phe.gov/Preparedness/mcm/Pages/skingraft-nuke-130730.aspx.
- U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Tactical Programs Division; Office of Emergency Management. 2020. Chemical hazards emergency medical management.
- U.S. Food and Drug Administration. 2003. FDA approves pyridostigmine bromide as pretreatment against nerve gas.
- U.S. Food and Drug Administration. 2011. Drug approval package – nithiodote.
- U.S. Food and Drug Administration. 2019a. 510(k) premarket notification for Silverlon wound contact, burn contact dressings.
- U.S. Food and Drug Administration. 2019b. Animal Rule information. https://www.fda.gov/emergency-preparedness-and-response/mcm-regulatory-science/animal-rule-information.
- U.S. Food and Drug Administration. 2019c. Development & approval process: drugs; [accessed 2020 Sep 27]. https://www.fda.gov/drugs/development-approval-process-drugs.
- U.S. Food and Drug Administration. 2020a. 510(k) submission process; [accessed 2020 Sep 7]. https://www.fda.gov/medical-devices/premarket-notification-510k/510k-submission-process.
- U.S. Food and Drug Administration. 2020b. Emergency use authorization; [accessed 2020 Sep 27]. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#othercurrenteuas.
- U.S. Food and Drug Administration. 2020c. Expiration dating extension; [accessed 2020 Sep 27]. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/expiration-dating-extension.
- U.S. Food and Drug Administration. 2020d. Investigational New Drug (IND) application; [accessed 2020 Sep 27]. https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application.
- U.S. Food and Drug Administration. 2020e. MCMi program update FY19: FDA medical countermeasures initiative.
- United States Government Accountability Office. 2011. Developing and acquiring medical countermeasures against chemical, biological, radiological, and nuclear agents [report no. GAO-11-567T].
- United States Government Accountability Office. 2014. DOD has strengthened coordination on medical countermeasures but can improve its process for threat prioritization [report no. GAO-14-442].
- Unknown. 2015. HHS to procure two inhalational anthrax treatments for national supply; [accessed 2020 Sep 27]. https://www.infectioncontroltoday.com/view/hhs-procure-two-inhalational-anthrax-treatments-national-supply.
- USASpending.gov. 2010. TAS::75 0140::TAS emergent biodefense operations lansings development and licensure of a large scale manufacturing process for biothrax; [accessed 2020 Sep 27].
- USASpending.gov. 2011. NanoDTPA oral Zn-DTPA capsules for radionuclide decorporation; [accessed 2020 Sep 27]. https://www.usaspending.gov/#/award/CONT_AWD_HHSO100201100047C_7505_-NONE-_-NONE-.
- USASpending.gov. 2017. Delivery order HHSD2002017F94479 for pralidoxime; [accessed 2020 Sep 27]. https://www.usaspending.gov/award/CONT_AWD_HHSD2002017F94479_7523_V797P5032B_3600.
- USASpending.gov. 2019. Purchase order for Baxter Healthcare Corporation for pralidoxime; [accessed 2020 Sep 27]. https://www.usaspending.gov/award/CONT_AWD_75A50119P00041_7505_-NONE-_-NONE-.
- USASpending.gov. 2020. NanoDTPA oral Zn-DTPA capsules for radionuclide decorporation; [accessed 2020 Sep 20]. https://www.usaspending.gov/award/CONT_AWD_HHSO100201100047C_7505_-NONE-_-NONE-.
- Zhang Y, Zhao J, Guan L, Mao L, Li S, Zhao J. 2020. Histone H4 aggravates inflammatory injury through TLR4 in chlorine gas-induced acute respiratory distress syndrome. J Occup Med Toxicol. 15:31.